Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148245 · ClinicalTrials.gov registry record
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
A clinical trial of Cutaneous Melanoma and Cutaneous Melanoma, Stage III, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07148245 is a study of Cutaneous Melanoma and Cutaneous Melanoma, Stage III that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 300 participants, below the 357-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07148245, a study of Cutaneous Melanoma and Cutaneous Melanoma, Stage III, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom management; inform treatment decision making; and refine ICI-symptom instrument development. Furthermore, given the limited knowledge in this area, the identification of demographic, clinical, environmental, and molecular risk factors associated with a worse symptom experience is warranted. This is a longitudinal, prospective study evaluating the symptoms that immune checkpoint inhibitors may cause in patients with cutaneous melanoma.
Conditions Studied
Interventions
- OTHER Medical Chart Review
- PROCEDURE Blood Sample
- OTHER Health Related Quality of Life Questionnaires (HRQoL)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148245
The ClinicalTrials.gov registry entry for NCT07148245 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (16% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Medical Chart Review is the first listed.
NCT07148245 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07148245 about?
NCT07148245 is a clinical study titled "Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma". The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the im...
What is the current status of trial NCT07148245?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-10-13. Estimated completion is 2027-06-30.
What conditions does trial NCT07148245 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV.
What interventions are being tested in trial NCT07148245?
The interventions under investigation include: Medical Chart Review (OTHER), Blood Sample (PROCEDURE), Health Related Quality of Life Questionnaires (HRQoL) (OTHER).
Who is sponsoring clinical trial NCT07148245?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148245 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.